NGLY1 Deficiency
Conditions
Keywords
Gene Therapy, Intervention study, Infusions, Intraventricular, Enzyme Replacement Therapy
Brief summary
A non-randomized, open-label, Phase 1/2/3 study of a single intracerebroventricular (ICV) administration of a gene replacement therapy (GS-100) in participants who are 2 to 18 years old with NGLY1 Deficiency.
Detailed description
This study is a first in human (FIH) open-label study designed to assess the safety and efficacy of administration of an adeno-associated viral vector serotype 9 (AAV9) carrying the gene encoding N-glycanase 1 (NGLY1) in subjects ages 2-18 years old with NGLY1 Deficiency. The study treatment is delivered via intracerebroventricular (ICV) injection. Phase 1/2 is the open-label dose finding part of the study designed to evaluate the safety and preliminary efficacy of GS-100 at 4 different dose levels and to select a safe and efficacious dose for the Phase 3 part of the study. Enrollment of 7 participants in the Phase 1/2 part of the study is complete. Phase 3 is evaluating the efficacy and safety of GS-100 at the Selected Dose determined in the Phase 1/2 part of the study (Mid dose: 1e15 for 6-18-year-olds, 8.7e14 for 2-5-year-olds). Enrollment of 3 participants in the Phase 3 part of the study is complete.
Interventions
GENETICGS-100
A single intracerebroventricular (ICV) dose of GS-100
Sponsors
Grace Science, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study treatment will be delivered via intracerebroventricular (ICV) infusion.
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be 2 to 18 years of age, inclusive, at the time of signing the informed consent form (ICF) * Patients with a documented diagnosis of NGLY1 Deficiency based on detection of biallelic variants in the NGLY1 gene via molecular genetic sequencing * Elevated GNA levels may be considered alongside genetic sequencing data and other clinical data to assist with diagnosis confirmation * Patients with two or more of the following clinical features typical of NGLY1 Deficiency: 1. Global developmental delay and/or intellectual disability 2. Hyperkinetic movement disorder 3. Transient elevation of transaminases 4. (Hypo)alacrima 5. Peripheral neuropathy * For patients with epilepsy who require anti-seizure medications for seizure control: must be on a stable regimen for 28 days prior to enrollment * Patients willing and capable per investigator opinion to comply with study procedures and requirements * Females of childbearing potential must have a negative serum pregnancy test at screening and must agree to use an acceptable method of highly effective contraception from screening through the end of the study * Patients or parent(s)/guardian(s) must be willing and able to provide written consent after the nature of the study has been explained and prior to performance of any research-related procedures
Exclusion criteria
* For Phase 1/2 only: Patients at Level 5 of both the Gross Motor Function Classification System Expanded and Revised (GMFCS E\&R) and the Communication Function Classification System (CFCS) scales as assessed by the investigator * Contraindication to use of corticosteroids or history of a condition that could worsen with corticosteroid therapy, as assessed, and determined by the investigator * Signs / symptoms of increased intracranial pressure (ICP), history of space occupying lesion, or ventricular shunt that would preclude ICV procedures or safety assessments a. If clinical signs or symptoms of increased ICP are present (such as headache, vomiting, altered mental status), an ophthalmology examination will be performed to assess for papilledema and/or venous pulsations * Any comorbid medical or behavioral condition that, in the opinion of the investigator, may adversely affect the safety and well-being of the participant during the study, interfere with completion of the study procedures or follow-up, or compound interpretation of the study results * Vital signs outside age-based normative values: 1. Blood pressure: values \> 99th percentile as cited in the National Heart, Lung and Blood Institute (NHLBI) guidelines for blood pressure levels based on subject's age, height and sex (nhlbi.nih.gov/files/docs/guidelines/child\_tbl.pdf) 2. Temperature: evidence of fever such as body temperature (e.g., orally measured) of 38.0°C (100.3°F) 3. Respiratory rate in breaths per minute: toddler (1-3 years old): 24-40; preschooler (4-5 years old): 22-34 breaths per minute; school-aged child (6-12 years old): 18-30 breaths per minute; adolescence (13-18 years old): 12-16. 4. Oxygen saturation on room air \< 92% * Any condition that in the opinion of the investigator or the study medical monitor would prevent the patient from fully complying with the requirements of the study (including the corticosteroid treatment outline in the protocol) and/or would impact or interfere with the evaluation and interpretation of patient safety or efficacy results * Known allergy or hypersensitivity to the GS-100 investigational product formulation * Prior treatment with gene therapy * Treatment with any investigational product (IP) within 30 days or 5 half-lives of the IP, whichever is longer, prior to screening period. For patients who have received a prior investigational product, all ongoing AEs experienced while receiving the investigational product must have been resolved prior to screening for this study * Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study that does not interfere with the requirements of the current protocol and does not have the potential to impact the evaluation of safety and efficacy of GS-100 * Coagulation dysfunction at screening as defined by the following: a. INR: ≥1.4 x Upper Limit of Normal (ULN) * Any current infection with hepatitis B virus (HBV) as evidenced by as evidenced by positive HBV surface antigen (HBsAg), and/or HBV core antibody (HBcAb) at screening. Isolated HBsAb positivity for HBV vaccination in conjunction with negative confirmatory HBV DNA testing at screening is not exclusionary * Any prior or current infection with hepatitis C virus (HCV) as evidenced by positive HCV antibody testing and confirmed by positive polymerase chain reaction (PCR) RNA testing at screening * Any of the following abnormal laboratory values: 1. Hemoglobin level: \< 9 g/dL 2. Absolute neutrophil count: \< 1000 cells/microliter 3. Platelet count: \< 100,000/mm3 4. Creatinine: \> 1.25 x ULN * Have a major surgery planned during the screening period through 52 weeks following GS-100 infusion, including major dental procedures (e.g., wisdom tooth extraction) * Pregnant or breastfeeding female patient * Patients that demonstrate elevated serum adrenocorticotropic hormone (ACTH) 1.5 times the upper limit of normal for the reference range must be referred for consultation with a pediatric endocrinologist to rule out primary adrenal insufficiency prior to being enrolled into the study. Patients may re-screen for participation in the study after medical consultation and / or possible treatment has been initiated to address any adrenal insufficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1/2 (Dose Finding): Safety and Tolerability of GS-100 | Baseline through Week 52 | Incidence of adverse events (AEs) and serious AEs (SAEs) |
| Phase 3 (Pivotal): Efficacy of GS-100 at the Selected Dose | Baseline through Week 52 | Improvement in one or more domains of the 88-item Gross Motor Function Measure (GMFM-88) from Baseline to Week 52 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Individual domains of the Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales | Baseline through Week 52 | Change in total Raw Scores and Growth Score Values (GSVs) will be analyzed. Raw Scores range 0-162; GSVs range 428-559; a higher score reflects a higher level of skill. |
| Clinical Global Impression of Change (CGI-C) | Baseline through Week 52 | Change in value relative to Baseline; range of values is 1-7, with 1 being marked improvement |
| Clinical Global Impression of Severity (CGI-S) | Baseline through Week 52 | Change in value; range of values is 1-7, with 1 being normal/no impairment |
| Videotaped movement disorder assessments | Baseline through Week 52 | Change in movement disorder as captured by videotaped assessment |
| Sitting/standing assessment | Baseline through Week 52 | Change in ability to sit, come to sitting, stand, come to standing, and walk |
| Failure to thrive | Baseline through Week 52 | Change in weight (Z-score) |
| Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) | Baseline through Week 52 | Change in standard scores; standard scores are based on a mean of 100 and a standard deviation of 15; a higher score reflects a higher level of skill |
| Caregiver Global Impression of Change (CaGI-C) | Baseline through Week 52 | Change in value relative to Baseline; range of values is 1-7, with 1 being marked improvement |
| Caregiver Global Impression of Severity (CaGI-S) | Baseline through Week 52 | Change in value; range from 1-7, with 1 being normal/no impairment |
| Nerve conduction velocity (NCV) | Baseline through Week 52 | Change in peripheral nerve function |
| Seizure frequency in subjects with seizures | Baseline through Week 52 | Change in seizure frequency as measured by seizure diaries |
Countries
United States
Outcome results
None listed